Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism

American Journal of Hematology

Volumn 82, Issue 6, 2007, Pages 419-426

  Jillella, Anand P ^a   Shafer, Danielle ^b   Klumpp, Thomas R ^b   Emmons, Robert V B ^b   Mangan, Kenneth F ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Cyclophosphamide; Fludarabine; Graft failure; Graft rejection; Mini transplant; Mixed chimerism; Nonmyeloablative transplant

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ARTICLE; BLEEDING; CAUSE OF DEATH; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DONOR LYMPHOCYTE INFUSION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; INCIDENCE; INFECTION; LYMPHOCYTOMA; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; VOMITING;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHIMERISM; CHRONIC DISEASE; COHORT STUDIES; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; INJECTIONS, INTRAVENOUS; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VIDARABINE;

EID: 34249808218     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20862     Document Type: Article

References (29)

1. Thomas ED. Karnofsky memorial lecture. Bone marrow transplantation for malignant diseases. J Clin Oncol 1983;1:517-531.
2. Bortin MM, Horowitz MM, Rimm AA. Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988-1990 survey. Ann Intern Med 1992;116:505-512.
3. Applebaum FR, Sullivan KM, Buckner CD, et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation and marrow transplantation. J Clin Oncol 1987; 5:1340-1347.
4. Van Besien KW, Khouri IF, Giralt SA, et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management. J Clin Oncol 1995;13:1096-1102.
5. Klingemann HG, Storb R, Fefer A, et al. Bone marrow transplantation in patients aged 45 years and older. Blood 1986;65: 770-776.
6. Ringden O, Horowitz MH, Gale RP, et al. Outcome after allogeneic bone marrow transplant for leukemia in older patients. JAMA 1993;270:57-60.
7. Slavin S, Nagler A, Naparstek E, et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;9:756-763.
8. Childs R, Bahceci E, Clave E, et al. Non-myeloablative allogeneic peripheral blood stem cell transplants (PBSCT) for malignant disease reduces transplant related mortality (TRM). Blood 1998;92:137a.
9. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993;82:1695-1700.
10. Ferrara F, Palmieri S, Pocali B, et al. De novo acute myeloid leukemia with multilineage dysplasia: Treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG). Eur J Haematol 2002;68:203-209.
11. Rao SS, Peters SO, Crittendon RB, Stewart FM, Quesenberry P. Stem cell transplantation in the normal nonmyeloablative host: Relationship between cell dose, schedule and engraftmet. Exp Hematol 1997;25:114-121.
12. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical "three loci" incompatible transplants in leukemia by addition of recombinant human granulocyte colony-stimulating factor-modified peripheral blood progenitor cells to bone marrow inoculum. Blood 1994;84:3948-3954.
13. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94:3234-3241.
14. Brinchmann JE, Vartdal F, Guadernack G, et al. Direct immunomagnetic quantification of lymphocyte subsets in blood. Clin Exp Immunol 1988;71:182-186.
15. Tzeng CH, Lyou JY, Chen YR, et al. Determination of sibship by PCR-amplified short tandem repeat analysis in Taiwan. Transfusion 2000;40:840-845.
16. Glucksberg S, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of HLA-matched sibling donors. Transplantation 1974;18:295-304.
17. Shulman HM, Sullivan KM, Weiden PI. Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-217.
18. Storb R, Prentice RL, Thomas ED, et al. Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia. Br J Haematol 1983;55:573-585.
19. Storb R, Blume KG, O'Donnell MR, et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: The experience in four centers. Biol Blood Marrow Transplant 2001; 7:39-44.
20. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985;313:765-771.
21. Patterson J, Prentice HG, Brenner MK, et al. Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol 1986;63:221-230.
22. Barge AJ, Johnson G, Witherspoon R, Torok-Storb B. Antibody-mediated marrow failure after allogeneic bone marrow transplantation. Blood 1989;74:1477-1480.
23. Kernan NA, Flomenberg N, Dupont B, O'Reilly RJ. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Transplantation 1987;43: 842-847.
24. Corradini P, Tarella C, Olivieri A, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor risk hematologic malignancies. Blood 2000;99:75-82.
25. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-2824.
26. Khouri IF, Champlin RE. Nommyeloablative stem cell transplantation for lymphoma. Semin Oncol 2004;31:22-27.
27. Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004;104:1550-1558.
28. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004;104:3535-3542.
29. Petersen SL, Madsen HO, Ryder LP, et al. Haematopoietic stem cell transplantation with non-myeloablative conditioning in the outpatient setting: Results, complications and admission requirements in a single institution. Br J Haematol 2004;125:225-231.